2024-519491-60-00Not yet recruitingPhase 1/2
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Aug 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 27 Apr 2026
- Start date
- 1 Jul 2026
- Lead sponsor
- Universitaetsklinikum Tuebingen AöR
- Diseases
- ANCA-associated vasculitis, Multiple sclerosis, Rheumatoid arthritis, Systemic sclerosis (scleroderma)
- EU CT number
- 2024-519491-60-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 36
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose autoimmune disease has come back or has not responded to earlier treatment. It tests a CAR-T cell therapy, UKT-CART19.1.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory (returned or not responding to treatment) autoimmune disease: ANCA associated vasculitis, immune thrombocytopenic purpura, multiple sclerosis, rheumatoid arthritis, pemphigus vulgaris, systemic sclerosis, or inflammatory idiopathic myositis.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Germany | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.